Harm reduction works, and the evidence is not particularly close. Across overdose prevention, infectious disease control, crime rates, housing stability, and pathways into treatment, decades of data show these programs reduce deaths, save money, and don’t create the neighborhood problems critics predict. Here’s what the numbers actually look like.
Overdose Deaths Drop Sharply Near Safe Consumption Sites
The most direct test of harm reduction is whether it keeps people alive. Supervised consumption sites, where people use pre-obtained drugs under medical watch, have never recorded a fatal overdose on-site. But the more important question is whether they reduce deaths in the surrounding community, not just inside the building.
A 2024 systematic review covering studies from 2016 onward found that neighborhoods within 500 meters of a supervised consumption site had 67% fewer overdose deaths per 100,000 people after the site opened. Areas farther away saw a smaller, non-significant decline of about 24%. That sharp, localized drop is consistent with the simplest explanation: people who would otherwise overdose alone are instead overdosing where someone can intervene.
Naloxone distribution, the other major overdose prevention tool, shows a similar pattern. A study of pharmacy-based naloxone programs found that opioid fatality rates declined by about 16% per year in communities after standing-order naloxone dispensing was implemented. The World Health Organization now recommends that anyone likely to witness an overdose, including people who use drugs and their family and friends, should have access to naloxone and training in how to use it.
HIV and Hepatitis C Rates Cut in Half
Syringe service programs, sometimes called needle exchanges, provide sterile injection equipment so people aren’t sharing contaminated needles. According to HIV.gov, these programs are associated with roughly a 50% reduction in both HIV and hepatitis C incidence among people who inject drugs. That’s not a modest effect. In the context of two epidemics that have killed millions of people worldwide, cutting transmission in half with a relatively low-cost intervention is a major public health win.
These programs also serve as a point of contact for testing and diagnosis. Many people who use syringe services get their first HIV or hepatitis C diagnosis through on-site screening, which means earlier treatment and less onward transmission.
The Cost Savings Are Enormous
Harm reduction is cheap compared to the alternatives. A cost-effectiveness analysis published in the Journal of Managed Care & Specialty Pharmacy calculated the savings from preventing hepatitis C among people who inject opioids. Syringe service programs alone saved public payers roughly $363,800 per hepatitis C case avoided, factoring in both direct medical costs and the broader costs of injection drug use. Combining syringe services with medications for opioid use disorder saved about $347,600 per case avoided and was the most effective strategy overall, preventing 72 hepatitis C cases per 100 people served.
These figures account for what happens when you don’t intervene: emergency room visits, long-term hepatitis C treatment (which can cost tens of thousands of dollars per patient), hospitalizations for infections, and costs associated with drug-related crime. Harm reduction doesn’t just shift the bill. It shrinks it.
Crime Goes Down, Not Up
The most common objection to harm reduction facilities is that they’ll attract crime and public drug use. The research consistently shows the opposite. A systematic review in the American Journal of Preventive Medicine examined seven studies on crime and public nuisance around supervised injection sites. No study found a significant increase in crime. Several found decreases.
In Vancouver, a study using an interrupted time series design found that crime didn’t meaningfully change across most of the city after the supervised injection site opened, except in the immediate district around the facility, where there was a sustained decrease in crime. In Sydney, both residents and business owners reported seeing less public injecting and fewer discarded syringes over the five years following the opening of a supervised injection facility. A separate Vancouver study found significant reductions in public injection, publicly discarded syringes, and injection-related litter after the site opened.
When a supervised consumption site had no wait time and people could walk in immediately, public injecting nearby was significantly less likely. The mechanism is straightforward: if there’s an available indoor space, fewer people inject outside.
Harm Reduction Leads People Into Treatment
One persistent criticism is that harm reduction “enables” drug use by removing consequences. The data tell a different story. People who access syringe service programs are approximately five times more likely to enter addiction treatment and three times more likely to stop using drugs compared to people who don’t use these services. Among clients at syringe programs that didn’t directly offer medications for opioid use disorder, 40% sought drug treatment services on their own. About 22% were receiving methadone and 8% were on buprenorphine.
This makes practical sense. Harm reduction programs are often the first point of sustained, non-judgmental contact between a person who uses drugs and the health system. Staff build trust over time. When someone is ready to explore treatment, the connection already exists. The WHO identifies this bridge function as a core benefit, noting that fewer than 10% of the estimated 64 million people living with drug use disorders worldwide currently have access to treatment. Harm reduction widens that narrow doorway.
Housing First Programs Show the Model Scales
Harm reduction principles extend beyond drugs. Housing First programs apply the same logic to homelessness: instead of requiring people to get sober and complete treatment before receiving housing, you give them a stable place to live and offer services without mandating participation.
A study of chronically homeless individuals with both mental illness and substance use disorders found that those placed in a Housing First program obtained housing faster, stayed housed longer, and reported greater sense of choice over their lives compared to those in traditional programs. The program maintained approximately 80% housing retention, a rate that directly challenged the widespread assumption among service providers that chronically homeless people are “not housing ready.” Participants weren’t required to be sober or in treatment. They were housed, and outcomes improved across the board.
Why the Debate Persists
If the evidence is this consistent, why does the question “does harm reduction actually work” still get searched so often? Part of the answer is that harm reduction feels counterintuitive. It asks society to accept that people will continue using drugs and to focus on keeping them alive and healthy rather than demanding abstinence first. That clashes with deeply held moral frameworks about addiction and personal responsibility.
Another factor is that harm reduction doesn’t claim to solve addiction. It claims to reduce the damage addiction causes, to individuals, families, neighborhoods, and public budgets, while keeping people alive long enough to access treatment when they’re ready. By that standard, the evidence is overwhelming. Overdose deaths drop. Infectious disease transmission falls. Crime doesn’t increase. Costs go down. And people are more likely, not less likely, to eventually seek treatment.